Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	Health Quality Ontario (HQO)	Intrathecal drug delivery systems for noncancer pain: a health technology assessment
2016	NIHR Health Technology Assessment programme	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
2016	Health Quality Ontario (HQO)	Left ventricular assist devices for destination therapy: a health technology assessment
2016	Health Quality Ontario (HQO)	Mechanical thrombectomy in patients with acute ischemic stroke: a health technology assessment
2016	Adelaide Health Technology Assessment (AHTA)	MALDI-TOF for detection of antibiotic resistant bacteria
2016	Gesundheit Osterreich GmbH (GOeG)	[Recent evidence on drug therapy of psychological and behavioral symptoms in Alzheimer's dementia]
2016	Health Quality Ontario (HQO)	Repetitive transcranial magnetic stimulation for treatment- resistant depression: a systematic review and meta-analysis of randomized controlled trials
2016	Adelaide Health Technology Assessment (AHTA)	Transcranial magnetic resonance-guided focused ultrasound and deep brain stimulation for refractory depression
2016	Health Quality Ontario (HQO)	Repetitive transcranial magnetic stimulation for treatment-resistant depression: an economic analysis
2016	Adelaide Health Technology Assessment (AHTA)	Gene expression profiling of breast cancer
2016	Health Quality Ontario (HQO)	Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Vepoloxamer for vaso-occlusive crises in sickle cell disease – first line
2016	Adelaide Health Technology Assessment (AHTA)	Enhanced liver fibrosis test
2016	The Swedish Council on Health Technology Assessment (SBU)	[Anal sphincter injuries]
2016	Health Quality Ontario (HQO)	Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: an economic analysis
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ofatumumab (Arzerra) for refractory follicular lymphoma – third line in combination with bendamustine
2016	Adelaide Health Technology Assessment (AHTA)	Stenting versus medical therapy for atherosclerotic renal artery stenosis
2016	National Institute for Health and Care Excellence (NICE)	High-throughput non-invasive prenatal testing for fetal RHD genotype. NICE diagnostics guidance 25
2016	The Swedish Council on Health Technology Assessment (SBU)	Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2016	Health Quality Ontario (HQO)	Intrathecal drug delivery systems for cancer pain and noncancer pain: OHTAC recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Medidur for non-infectious posterior uveitis – second line
2016	Adelaide Health Technology Assessment (AHTA)	PATHFAST Presepsin chemiluminescent enzyme immunoassay for the diagnosis and prognosis of sepsis
2016	National Institute for Health and Care Excellence (NICE)	ImmunoCAP ISAC 112 for multiplex allergen testing. NICE diagnostics guidance 24
2016	The Swedish Council on Health Technology Assessment (SBU)	[Treatment of maternal birth injuries following vaginal birth – mapping of systematic reviews]
2016	Health Quality Ontario (HQO)	Left ventricular assist devices for destination therapy: OHTAC recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Epoetin alfa (Eprex) for anaemia in adults with low or intermediate-1 risk myelodysplastic syndromes
2016	Agency for Healthcare Research and Quality (AHRQ)	Outcome Measures Framework: Literature review. Findings and implications. Registry of Patient Registries
2016	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone]
2016	National Institute for Health and Care Excellence (NICE)	Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits). NICE diagnostics guidance 22
2016	The Swedish Council on Health Technology Assessment (SBU)	[Treatment for binge eating disorder]
2016	Health Quality Ontario (HQO)	Mechanical thrombectomy for patients with acute ischemic stroke: OHTAC recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Naldemedine for opioid-induced constipation in adults
2016	NIHR Health Technology Assessment programme	Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme
2016	The Swedish Council on Health Technology Assessment (SBU)	[Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Spectrum Disorders (FASD) – conditions and interventions]
2016	Health Quality Ontario (HQO)	Repetitive transcranial magnetic stimulation for treatment-resistant depression: OHTAC recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria – first line
2016	NIHR Health Services and Delivery Research programme	Towards improved decision support in the assessment and management of pain for people with dementia in hospital: a systematic meta-review and observational study
2016	Health Quality Ontario (HQO)	Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: OHTAC recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	KRN23 for X-linked hypophosphataemia in children aged 5-12 years – first line
2016	NIHR Health Services and Delivery Research programme	Patient-level information and costing systems (PLICSs): a mixed-methods study of current practice and future potential for the NHS health economy
2016	The Swedish Council on Health Technology Assessment (SBU)	[Occupational exposures and osteoarthritis]
2016	Technology Assessment at SickKids (TASK)	A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Empagliflozin (Jardiance) for preventing cardiovascular death in patients with type 2 diabetes mellitus and high cardiovascular risk
2016	NIHR Health Services and Delivery Research programme	A qualitative study of decision-making about the implantation of cardioverter defibrillators and deactivation during end-of-life care
2016	NIHR Health Technology Assessment programme	Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): a randomised controlled trial with cost-effectiveness analysis
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Empagliflozin (Jardiance) for type 1 diabetes – adjunctive therapy
2016	NIHR Public Health Research (PHR) programme	Health impacts of the Cambridgeshire Guided Busway: a natural experimental study
2016	NIHR Health Technology Assessment programme	The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pelareorep in combination with paclitaxel for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Mogamulizumab for relapsed or refractory cutaneous T-cell lymphoma – second and subsequent lines
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Hexyl aminolevulinate (Cevira) for cervical high-grade squamous intraepithelial lesions
2016	NIHR Health Technology Assessment programme	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Crizotinib (Xalkori) for advanced ROS1 positive non-small cell lung cancer – first line
2016	NIHR Health Technology Assessment programme	Improving outcomes for people in mental health crisis: a rapid synthesis of the evidence for available models of care
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Aldoxorubicin for metastatic, locally advanced or unresectable soft tissue sarcoma – second line
2016	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis and management of infantile hemangioma
2016	Agency for Healthcare Research and Quality (AHRQ)	Resident safety practices in nursing home settings
2016	Agency for Healthcare Research and Quality (AHRQ)	Contrast-induced nephropathy: comparative effects of different contrast media
2016	NIHR Public Health Research (PHR) programme	Active for Life Year 5: a cluster randomised controlled trial of a primary school-based intervention to increase levels of physical activity, decrease sedentary behaviour and improve diet
2016	European Network for Health Technology Assessment (EUnetHTA)	Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk
2016	NIHR Health Services and Delivery Research programme	The care of dying people in nursing homes and intensive care units: a qualitative mixed-methods study
2016	NIHR Health Technology Assessment programme	Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review
2016	NIHR Health Technology Assessment programme	Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Telehealth: mapping the evidence for patient outcomes from systematic reviews
2016	Agency for Healthcare Research and Quality (AHRQ)	Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review
2016	NIHR Health Technology Assessment programme	A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2)
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of collaborative care for depression in UK primary care (CADET): a cluster randomised controlled trial
2016	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures
2016	NIHR Health Technology Assessment programme	Intervention Now to Eliminate Repeat Unintended Pregnancy in Teenagers (INTERUPT): a systematic review of intervention effectiveness and cost-effectiveness, and qualitative and realist synthesis of implementation factors and user engagement
2016	NIHR Health Technology Assessment programme	Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort
2016	NIHR Health Services and Delivery Research programme	Development of risk models for the prediction of new or worsening acute kidney injury on or during hospital admission: a cohort and nested study
2016	NIHR Health Services and Delivery Research programme	Comparing the cost-effectiveness and clinical effectiveness of a new community in-reach rehabilitation service with the cost-effectiveness and clinical effectiveness of an established hospital-based rehabilitation service for older people: a pragmatic randomised controlled trial with microcost and qualitative analysis – the Community In-reach Rehabilitation And Care Transition (CIRACT) study
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)
2016	Belgian Health Care Knowledge Centre (KCE)	The role of biomarkers in ruling out cerebral lesions in mild cranial trauma
2016	NIHR Health Services and Delivery Research programme	Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)
2016	Belgian Health Care Knowledge Centre (KCE)	Elective caesarean section in low-risk women at term: consequences for mother and offspring
2016	Belgian Health Care Knowledge Centre (KCE)	Use of pneumococcal vaccines in the elderly an economic evaluation
2016	National Institute for Health and Care Excellence (NICE)	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NICE technology appraisal guidance 375
2016	Institute of Health Economics (IHE)	Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency
2016	National Institute for Health and Care Excellence (NICE)	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NICE technology appraisal guidance 377
2016	NIHR Health Technology Assessment programme	The relationship between pelvic vein incompetence and chronic pelvic pain in women: systematic reviews of diagnosis and treatment effectiveness
2016	Institute of Health Economics (IHE)	Endovenous thermal ablation interventions for symptomatic varicose veins of the legs – an update
2016	Health Sciences Institute in Aragon (IACS)	Efficacy, effectiveness, safety and efficiency of colloid solutions for pediatric surgery
2016	National Institute for Health and Care Excellence (NICE)	Ramucirumab for treating advanced gastric cancer or gastrooesophageal junction adenocarcinoma previously treated with chemotherapy. NICE technology appraisal guidance 378
2016	NIHR Health Technology Assessment programme	An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial)
2016	Institute of Health Economics (IHE)	Hysteroscopic tubal sterilization (using the Essure® system) – an update
2016	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 379
2016	NIHR Health Technology Assessment programme	The natural history of Chlamydia trachomatis infection in women: a multi parameter evidence synthesis
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care troponin testing in patients with symptoms suggestive of acute coronary syndrome: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Panobinostat for treating multiple myeloma after at least 2 previous treatments. NICE technology appraisal guidance 380
2016	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Iontophoresis assisted corneal crosslinking]
2016	National Institute for Health and Care Excellence (NICE)	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal). NICE technology appraisal guidance 382
2016	NIHR Health Technology Assessment programme	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial
2016	NIHR Health Services and Delivery Research programme	Demand management for planned care: a realist synthesis
2016	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Safety and effectiveness of LDL-aphaeresis in cerebrotendinous xanthomatosis]
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 384
2016	NIHR Health Technology Assessment programme	A programme of studies including assessment of diagnostic accuracy of school hearing screening tests and a cost-effectiveness model of school entry hearing screening programmes